At Rush University Medical Center, we are putting your safety first. For information about COVID-19, see the latest updates. Rush accepts donations to support our response effort, staff, and patients and families.
How you can devise a cancer prevention action plan.
How to love yourself — and your selfies — without filters or fillers.
SBRT for Localized Prostate Cancer Study
Clinical Trial Title:
A prospective evaluation of multi-parametric magnetic resonance imaging (mpMRI) guided stereotactic body radiation treatment for localized prostate cancer.
Clinical Trial Protocol ID:
15060207
Clinical Trial Investigator Name:
Dian Wang, MD, PhD
Clinical Trial Protocol Description:
A type of imaging called multi-parametric magnetic resonance imaging (mpMRI) has been approved to detect aggressive, high-grade, invasive prostate cancer. This is considered the standard care for prostate cancer. An MRI is a type of scan that uses magnets, radio waves, and a computer to produce images of body structures. The purpose of this study is to evaluate the effects, good and/or bad, of using mpMRI to guide high-dose radiation treatment for prostate cancer.
Clinical Trial Eligibility Criteria:
In order to participate you must meet the following criteria:
- Have a diagnosis of prostate cancer within 1 year.
- Have no distant metastases or regional lymph node involvement.
- Have no use of finasteride within 30 days.
- Have no use of dutasteride within 90 days.
This is a partial list of elgibility requirements.
Clinical Trial Area:
Genitourinary Cancers
Contact Email:
Contact Phone:
(312) CANCER-1
Contact Name:
Rush Cancer Center Clinical Trials Office